Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Arimoclomol→

Arimoclomol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
289893-25-0
Molecular formula
C14H20ClN3O3
Molecular weight
313.78 g/mol
Drug class
Small-molecule therapy for Niemann-Pick disease type Cmechanism-based pharmacological class not established
Mechanism of action
The mechanism(s) by which arimoclomol exerts its clinical effects in patients with Niemann-Pick disease type C is unknown, according to the US prescribing information. Proposed heat-shock-protein/lysosomal effects should not be presented as established clinical mechanism.
Indications / reported uses
  • In combination with miglustat for treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and paediatric patients aged 2 years and older under the US FDA Miplyffa indication

Sources: US FDA prescribing information — Miplyffa · US FDA — Miplyffa approval · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Arimoclomol Environmental Risk Assessment (ERA) (the Arimoclomol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.